Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was USD 0.052 million compared to USD 0.063 million a year ago. Revenue was USD 23.48 million compared to USD 18.53 million a year ago. Net loss was USD 23.66 million compared to net income of USD 2.15 million a year ago. Basic loss per share from continuing operations was USD 17.57 compared to basic earnings per share from continuing operations of USD 2.19 a year ago. Diluted loss per share from continuing operations was USD 17.57 compared to diluted earnings per share from continuing operations of USD 2.19 a year ago.